Breakthrough COVID-19 infections and perceived vaccine effectiveness

被引:3
|
作者
Neely, Stephen R. [1 ]
Hao, Feng [2 ]
机构
[1] Univ S Florida, Sch Publ Affairs, 4202 E Fowler Ave,SOC 107, Tampa, FL 33620 USA
[2] Univ S Florida, Dept Sociol, 4202 E Fowler Ave,SOC 107, Tampa, FL 33620 USA
关键词
COVID-19; Breakthrough infections; Vaccine efficacy; Vaccine hesitancy;
D O I
10.1016/j.vaccine.2023.11.032
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction: While SARS-CoV-2 vaccines provide significant protection against severe COVID-19 illness, breakthrough infections have sparked confusion among patients about the effectiveness of vaccination. It's unclear if (or to what extent) breakthrough infection experiences impact public perceptions of COVID-vaccine effectiveness, though the answer may have significant implications for public health communications and ongoing vaccine acceptance. Methods: We conducted a survey of 2,500 adults in the United States (February 27 - March 9, 2023) in order to better understand the relationship between breakthrough COVID-19 infections and perceived vaccine effectiveness. Survey respondents were selected using a stratified, quota sampling approach to ensure representativeness; analysis was conducted on responses from 1,928 participants who received a COVID-19 vaccine.Findings: Among those who tested positive for COVID-19 after being vaccinated, 21.18 % said that COVID-19 vaccines had been "less effective" than they initially expected, compared with 10.0 % of those who did not experience any breakthrough infections (X2 = 75.551; phi = 0.198; p <= 0.001). Those who experienced their own breakthrough infection were 1.37 times less likely to report perceived vaccine efficacy, while those whose family members experienced a breakthrough infection were 1.64 times less likely to report the same, ceteris paribus. The largest effect was observed among those who experienced both a personal and familial breakthrough infection. This group was almost two times less likely to describe COVID-19 vaccines as "very effective".Discussion: Breakthrough infections correlated with lower overall levels of perceived vaccine effectiveness, even after accounting for demographic and political considerations. Moving forward, public officials and health professionals should work proactively to ensure that breakthrough infections are understood in the broader context of overall vaccine effectiveness.
引用
收藏
页码:7689 / 7694
页数:6
相关论文
共 50 条
  • [21] Clinical characterization of COVID-19 breakthrough infections, Philippines
    Velasco, John Mark
    Vila, Vicente
    Diones, Paula Corazon
    Valderama, Maria Theresa
    Mendez, Cecille
    Turao-Agoncillo, Ma Melissa Monica
    Chinnawirotpisan, Piyawan
    Manasatienkij, Wudtichai
    Joonlasak, Khajohn
    Klungthong, Chonticha
    Jones, Anthony
    Fernandez, Stefan
    Navarro, Fatima Claire
    [J]. JOURNAL OF CLINICAL VIROLOGY, 2022, 150
  • [22] COVID-19 breakthrough infections in vaccinated healthcare workers
    Israeli, Eitan
    [J]. ISRAEL MEDICAL ASSOCIATION JOURNAL, 2021, 23 (11): : 698 - 698
  • [23] Breakthrough COVID-19 infections - Analyzing our experience
    Hussain, Aneela
    Sarfaraz, Samreen
    Anis, Sabiha
    Sheikh, Quratulain
    Rahim, Anum
    Behram, Shameem
    Shah, Rabeea
    Khan, Owais
    [J]. PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2023, 39 (05) : 1225 - 1231
  • [24] Factors Associated With COVID-19 Breakthrough Infections: Correspondence
    Mungmunpuntipantip, Rujitika
    Wiwanitkit, Viroj
    [J]. JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE, 2022, 64 (11) : E793 - E793
  • [25] Incidence and Risk Factors of COVID-19 Vaccine Breakthrough Infections: A Prospective Cohort Study in Belgium
    Stouten, Veerle
    Hubin, Pierre
    Haarhuis, Freek
    van Loenhout, Joris A. F.
    Billuart, Matthieu
    Brondeel, Ruben
    Braeye, Toon
    Van Oyen, Herman
    Wyndham-Thomas, Chloe
    Catteau, Lucy
    [J]. VIRUSES-BASEL, 2022, 14 (04):
  • [26] COVID-19 vaccination and breakthrough infections in patients with cancer
    Schmidt, A. L.
    Labaki, C.
    Hsu, C-Y
    Bakouny, Z.
    Balanchivadze, N.
    Berg, S. A.
    Blau, S.
    Daher, A.
    El Zarif, T.
    Friese, C. R.
    Griffiths, E. A.
    Hawley, J. E.
    Hayes-Lattin, B.
    Karivedu, V
    Latif, T.
    Mavromatis, B. H.
    McKay, R. R.
    Nagaraj, G.
    Nguyen, R. H.
    Panagiotou, O. A.
    Portuguese, A. J.
    Puc, M.
    Dutra, M. Santos
    Schroeder, B. A.
    Thakkar, A.
    Wulff-Burchfield, E. M.
    Mishra, S.
    Farmakiotis, D.
    Shyr, Yu
    Warner, J. L.
    Choueiri, T. K.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (03) : 340 - 346
  • [27] Hospitalisation among vaccine breakthrough COVID-19 infections (vol 21, pg 1485, 2021)
    Juthani, P., V
    Gupta, A.
    Borges, K. A.
    [J]. LANCET INFECTIOUS DISEASES, 2022, 22 (01): : E1 - E1
  • [28] Most breakthrough infections with the BNT162b2 COVID-19 vaccine are mild
    不详
    [J]. AORN JOURNAL, 2022, 115 (01) : P2 - P2
  • [29] From Conspiracy to Hesitancy: The Longitudinal Impact of COVID-19 Vaccine Conspiracy Theories on Perceived Vaccine Effectiveness
    Salazar-Fernandez, Camila
    Baeza-Rivera, Maria Jose
    Manriquez-Robles, Diego
    Salinas-Onate, Natalia
    Sallam, Malik
    [J]. VACCINES, 2023, 11 (07)
  • [30] Feasibility of Measuring Physiological Responses to Breakthrough Infections and COVID-19 Vaccine Using a Wearable Ring Sensor
    Pho, Gerald Norman
    Thigpen, Nina
    Patel, Shyamal
    Tily, Hal
    [J]. Digital Biomarkers, 2023, 7 (01) : 1 - 6